Polaryx Therapeutics, Inc. R&D decreased by 85.6% to $679.00K in Q1 2026 compared to the prior quarter.
High spending signals a commitment to future growth and innovation, though it reduces current period earnings.
Expenses related to the development of new products, services, and technologies, as well as the improvement of existing...
Tech leaders often spend a significant percentage of revenue on R&D to prevent disruption by competitors.
research_and_development| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $4.72M | $679.00K |
| QoQ Change | — | -85.6% |
| YoY Change | — | -85.6% |
| Segment | Q1 '25 | Q1 '26 |
|---|---|---|
| Lysosomal Storage Disorders | $372.00K | $679.00K |
| Total | $4.72M | $679.00K |